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molecular epidemiology survey (10) and found another 4 
cases (from 2008, 2011 [2 cases], and 2014). Three case-pa-
tients had emigrated from Romania, and all 5 case-patients 
lived in the same area of Almeria. These data indicated that 
the susceptible strain was circulating in the geographic/epi-
demiological context of the current case-patient before and 
when she tested positive for that strain; therefore, she likely 
acquired the susceptible strain through recent transmission.
The presence of susceptible and resistant strains in a 
patient should be considered even in moderate incidence set-
tings and where resistance rates are not high. Underdetection 
of these cases could lead to misinterpretation when MDR 
became apparent after treatment of susceptible strains. Diag-
nostic laboratories could easily screen for mixed infections 
by applying MIRU-VNTR. However, only by integrating 
clonal analysis, refined molecular typing, and epidemiologic 
data from universal genotyping programs can we clarify the 
reasons underlying complex MTB infections. For this case-
patient, a recent infection with a susceptible strain coincided 
with or could have triggered reactivation of a latent infection 
involving an MDR strain acquired through close contact years 
previously. We emphasize the alteration of the true clonal 
complexity of an infection induced by culturing specimens 
and that some commercial tests do not identify complex MTB 
infections. These findings are particularly relevant when the 
infection involves resistant strains such as those found in this 
case-patient.
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To the Editor: The epidemiology of cholera, espe-
cially in Africa and Asia, has periodically changed in subtle 
ways (1). The recent cholera epidemic in Haiti, a Carib-
bean country with no cholera cases in decades, affected 
>500,000 persons, caused ≈8,000 deaths, and brought this 
illness to the forefront of Haitian public health concerns 
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(2,3). This life-threatening disease is caused by Vibrio chol-
erae, a waterborne bacterium with >200 serogroups, 2 of 
which, O1 and O139, cause epidemic or pandemic chol-
era. V. cholerae O1 is categorized as classical and El Tor 
biotypes, which differ biochemically and have different 
levels of virulence. Classical strains typically cause more 
severe illness than El Tor strains, which result in mild or 
moderate and sometimes asymptomatic cases. However, El 
Tor strains have replaced classical strains as the cause of 
cholera; the classical biotype is believed to be extinct, and 
El Tor strains currently prevail. However, the genetic traits 
specific to classical strains are still present in environmen-
tal and clinical V. cholerae isolates. Currently, all clinical 
strains of V. cholerae in Kolkata produce classical cholera 
toxin. Such phenotypic and genetic changes in V. cholerae 
are being monitored worldwide.
Several phenotypic and genetic laboratory tests are 
used to determine whether isolates are classified as clas-
sical or El Tor biotypes. Among phenotypic traits distin-
guishing the 2 biotypes, sensitivity to polymyxin B (50 
U) is considered a reliable indicator and stable phenotype 
for biotyping. Research has shown that the genome of V. 
cholerae strains is undergoing cryptic changes that influ-
ence the strains’ virulence, rapid transmission, and spread 
(4). Our previous findings showed El Tor strains with few 
biotype traits of classical strains (5).
Since the seventh cholera pandemic, which occurred 
during the 1960s and 1970s and was caused by El Tor strains, 
the El Tor biotype had been resistant to polymyxin B, a cat-
ionic antimicrobial peptide. However, when cholera strains 
first appeared in patients in Kolkata, India, in June 2012, 
V. cholerae O1 was found to be sensitive to polymyxin B 
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Figure. Isolation profile of polymyxin 
B–sensitive Vibrio cholerae strains in 
Kolkata, India, 2003–2014. A) Yearly 
occurrence of polymyxin B sensitivity and 
resistance in V. cholerae O1 El Tor variant 
strains isolated from Kolkata patients. 
During the study period, 255 strains were 
tested; n values indicate the number of 
strains tested each year. Polymyxin B–
sensitive strains first appeared in Kolkata 
in June 2012. The first isolate in January 
2013 was resistant, but, thereafter, all 
strains isolated during 2013–2014 were 
sensitive to polymyxin B, a biotyping 
marker for classical strains. B) MIC of 
polymyxin B in El Tor variant strains 
(classical and El Tor). MICs are indicated 
by white arrows. Polymyxin B sensitivity, 
a characteristic of classical strains, was 
displayed by El Tor variant strains. Data 
represent 3 biologic repetitions.
(6). To determine whether this phenomenon occurred ear-
lier, we tested 255 clinical strains isolated from patients in 
Kolkata during 2003–2014 and found that, from March 
2013, polymyxin B–sensitive El Tor strains had replaced re-
sistant strains (Figure, panel A). The MIC of polymyxin B, 
determined by Etest (bioMérieux, Marcy l’Etoile, France), 
confirmed that the El Tor strains were susceptible to this an-
timicrobial drug (Figure, panel B). In this assay, the El Tor 
strain (N16961) was highly resistant to polymyxin B (MIC 
96 µg/mL), whereas the variant strains in Kolkata showed a 
drastic reduction in resistance (6,7).
To confirm additional changes in biotype attributes in 
the variant Kolkata isolates during 2003–2014, we used the 
Voges-Proskauer test to determine production of acetylmeth-
yl carbinol and found that the tested strains produced acetoin 
and were positive for chicken erythrocytes agglutination. 
The rtsC gene encoding the activator protein, which is absent 
from classical biotype strains but present in El Tor strains, 
was found in all the tested strains of the El Tor biotype. 
Biotype-specific CTX prophage repressor rstR was ampli-
fied with the El Tor–specific primers, indicating presence 
of El Tor rstR. The tcpA gene has distinct alleles specific to 
classical and El Tor biotypes of O1. Our study showed that 
all strains yielded amplicons with the El Tor-tcpA–specific 
primers but not with the classical-tcpA–specific primers. 
However, these strains had a single-base substitution at the 
266-nt position of tcpA, also present in variant strains from 
Haiti. Furthermore, Vibrio seventh pandemic (VSP) gene 
clusters VSP I and VSP II are unique to El Tor strains of 
the seventh pandemic. We found presence of VSP I and II 
encoding genes in all our tested strains, indicating that the 
strains are El Tor, but with specific classical traits. 
We also checked the strains’ sensitivity to many antimi-
crobial drugs: tetracycline, trimethoprim/sulfamethoxazole, 
streptomycin, erythromycin, gentamicin, ciprofloxacin, and 
azithromycin, and all strains were sensitive to all drugs ex-
cept trimethoprim/sulfamethoxazole and streptomycin. All 
strains isolated during 2013–2014 were fully resistant to tri-
methoprim/sulfamethoxazole and streptomycin, but 55% of 
strains isolated before 2012 were sensitive to these drugs.
Genes encoding lipid IVA acyltrasferase (msbB), bio-
film formation, antimicrobial peptide resistance (carR), and 
3 aminoacyl lipid modification (almEFG) have been shown 
to contribute to polymyxin resistance in V. cholerae (6–8). 
Analysis of these genes from the newly emerged polymyx-
in-B–sensitive strains may provide additional useful infor-
mation. We found that these strains contained Haitian vari-
ant ctxB (ctxB7) similar to the classical cholera toxin. Our 
earlier studies identified many new attributes of Haitian V. 
cholerae variant strains in Kolkata since 2003 (9,10). 
We report the emergence of El Tor strains produc-
ing classical cholera toxin. These strains have lost an El 
Tor biotype marker and acquired a vital classical biotype 
characteristic, a change that has probably altered the regu-
latory mechanisms of lipid A modification machinery in V. 
cholerae (6–8). This change is a major event in the history 
of cholera after 1961, when El Tor strains first appeared. 
The recent changes in V. cholerae O1 strains should be 
carefully monitored to determine their clinical and epide-
miologic implications.
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